StockData
Climb Bio, Inc. logo

Climb Bio, Inc. (CLYM) stock

CLYMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 7/30
$9.28−0.02 (-0.22%)

Close on Nov 19, 2026Market cap $533.01MP/E –Yield –

Climb Bio free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Climb Bio's free cash flow for the twelve months ending Dec 31, 2025 was -$54.54M. For fiscal 2025 it was -$54.54M.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$54.54M–
FY2024Dec 31, 2024-$15.56M–
FY2023Dec 31, 2023-$20.60M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$15.64M–
Q3 FY2025Sep 30, 2025-$12.25M-450.9%
Q4 FY2024Dec 31, 2024-$5.52M–
Q3 FY2024Sep 30, 2024-$7.56M–
Q4 FY2023Dec 31, 2023-$947.00K–
Q3 FY2023Sep 30, 2023$3.49M–

More Climb Bio figures

See a number that looks wrong?